GlobeNewswire: Cascadian Therapeutics, Inc. Contains the last 10 of 76 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T15:54:41ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/01/04/1283361/0/en/Cascadian-Therapeutics-Announces-2018-Outlook-and-Recent-Progress.html?f=22&fvtc=4&fvtv=23945Cascadian Therapeutics Announces 2018 Outlook and Recent Progress2018-01-04T13:30:00Z<![CDATA[SEATTLE, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced an overview of recent progress for tucatinib, an investigational oral, small molecule kinase inhibitor that is highly selective for HER2 and the Company’s lead product in development for the treatment of HER2 overexpressing cancers, in addition to several anticipated key objectives for 2018.]]>https://www.globenewswire.com/news-release/2018/01/02/1277056/0/en/Cascadian-Therapeutics-Receives-Pediatric-Investigation-Plan-Waiver-from-the-European-Medicines-Agency.html?f=22&fvtc=4&fvtv=23945Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency2018-01-02T13:30:00Z<![CDATA[Removes Requirement for Pediatric Clinical Studies to Support Tucatinib Market Authorization Application for Treatment of Metastatic Breast Cancer in Europe Removes Requirement for Pediatric Clinical Studies to Support Tucatinib Market Authorization Application for Treatment of Metastatic Breast Cancer in Europe]]>https://www.globenewswire.com/news-release/2017/12/13/1261273/0/en/Cascadian-Therapeutics-Added-to-the-Nasdaq-Biotechnology-Index.html?f=22&fvtc=4&fvtv=23945Cascadian Therapeutics Added to the Nasdaq Biotechnology Index2017-12-13T13:35:00Z<![CDATA[SEATTLE, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (Nasdaq:CASC), a clinical-stage biopharmaceutical company, today announced that it has been selected for addition to the Nasdaq Biotechnology Index® (Nasdaq:NBI), which will become effective prior to U.S. market open on Monday, December 18, 2017.]]>https://www.globenewswire.com/news-release/2017/12/07/1247752/0/en/Prolonged-Progression-Free-Survival-Reinforces-Tucatinib-s-Potential-for-Patients-with-Advanced-HER2-Metastatic-Breast-Cancer.html?f=22&fvtc=4&fvtv=23945Prolonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Cancer 2017-12-07T21:05:00Z<![CDATA[Subgroup Analysis from Two Ongoing Combination Studies of Tucatinib Demonstrates Prolonged PFS Benefit Regardless of Presence of Brain Metastases or Patient Characteristics Subgroup Analysis from Two Ongoing Combination Studies of Tucatinib Demonstrates Prolonged PFS Benefit Regardless of Presence of Brain Metastases or Patient Characteristics ]]>https://www.globenewswire.com/news-release/2017/11/08/1178072/0/en/Cascadian-Therapeutics-Reports-Third-Quarter-2017-Financial-Results.html?f=22&fvtc=4&fvtv=23945Cascadian Therapeutics Reports Third Quarter 2017 Financial Results2017-11-08T21:01:00Z<![CDATA[Conference Call Scheduled for Today at 4:30 p.m. ET Conference Call Scheduled for Today at 4:30 p.m. ET]]>https://www.globenewswire.com/news-release/2017/11/01/1172319/0/en/Cascadian-Therapeutics-to-Report-Third-Quarter-2017-Financial-Results-on-November-8-2017.html?f=22&fvtc=4&fvtv=23945Cascadian Therapeutics to Report Third Quarter 2017 Financial Results on November 8, 20172017-11-01T13:19:05Z<![CDATA[SEATTLE, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter financial results after the close of the U.S. financial markets on Wednesday, November 8, 2017. Following the financial results announcement, members of management will host a conference call and live audio webcast to discuss the results and provide a general corporate update. Access to the conference call can be obtained as follows:]]>https://www.globenewswire.com/news-release/2017/10/24/1152329/0/en/Cascadian-Therapeutics-to-Participate-in-Panel-Discussions-at-Two-Conferences-in-November.html?f=22&fvtc=4&fvtv=23945Cascadian Therapeutics to Participate in Panel Discussions at Two Conferences in November2017-10-24T12:05:00Z<![CDATA[SEATTLE, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that Scott D. Myers, President and Chief Executive Officer, will participate in two panel discussions in the month of November.]]>Scott D. Myers, President and CEO, Cascadian Therapeutics, Inc.Scott D. Myers, Cascadian Therapeuticshttps://www.globenewswire.com/news-release/2017/09/27/1133644/0/en/Cascadian-Therapeutics-Announces-FDA-Orphan-Drug-Designation-Granted-to-Tucatinib-for-the-Treatment-of-HER2-Metastatic-Colorectal-Cancer.html?f=22&fvtc=4&fvtv=23945Cascadian Therapeutics Announces FDA Orphan Drug Designation Granted to Tucatinib for the Treatment of HER2+ Metastatic Colorectal Cancer2017-09-27T11:00:00Z<![CDATA[SEATTLE, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has granted orphan drug designation to tucatinib for the treatment of HER2-positive (HER2+) metastatic colorectal cancer. Tucatinib is an investigational oral, small molecule kinase inhibitor that is highly selective for HER2 and is the Company’s lead product in development.]]>https://www.globenewswire.com/news-release/2017/09/20/1125267/0/en/Cascadian-Therapeutics-to-Present-at-the-Cantor-Fitzgerald-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=23945Cascadian Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference2017-09-20T13:00:00Z<![CDATA[SEATTLE, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that management will present at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2017, at 9:45 a.m. EDT / 6:45 a.m. PDT in New York City.]]>https://www.globenewswire.com/news-release/2017/09/11/1117350/0/en/Tucatinib-Data-in-Multiple-Tumor-Types-Presented-at-the-European-Society-for-Medical-Oncology-ESMO-2017-Congress.html?f=22&fvtc=4&fvtv=23945Tucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 Congress2017-09-11T10:00:00Z<![CDATA[Results from Pooled Analysis Support the Potential Utility of Tucatinib for Patients with HER2+ Metastatic Breast Cancer with Brain Metastases]]>